Volume 94, number 2

FEBS LETTERS

October 1978

# THE ABSOLUTE CONFIGURATION OF THE NATURAL 25,26-DIHYDROXYCHOLECALCIFEROL

J. REDEL, N. BAZELY, Y. TANAKA<sup>+</sup> and H. F. DELUCA<sup>+</sup>

Institut de Rhumatologie, Centre de Recherches sur les Maladies Ostéo-Articulaires (U. 5 INSERM, ERA 337 CNRS), Hôpital Cochin, 27, rue du Fauborg Saint-Jacques, 75674 Paris Cédex 14, France and <sup>+</sup>Department of Biochemistry, College of Agricultural and Life Sciences, University of Wisconsin-Madison, WI 53706, USA

Received 12 July 1978

### 1. Introduction

Two of us have reported [1,2] the synthesis of the metabolite of vitamin  $D_3$  25,26-dihydroxycholecalciferol (25,26(OH)<sub>2</sub> $D_3$ ), which led to a mixture of the C-25 epimers and more recently [3] the resolution of these latter by HPLC. The absolute configuration of the epimers could be established [4] by X-ray diffraction analysis. One of these epimers must be identical with the natural metabolite 25,26(OH)<sub>2</sub> $D_3$ isolated from porcine plasma [5] and more recently generated biologically [6]. Its configuration at C-25 remained unknown.

The present report describes the identification of the natural  $25,26(OH)_2D_3$  with  $25R,26(OH)_2D_3$ . It was achieved by HPL co-C of their 3,25,26-Tris— TMS derivatives by a procedure similar to that used in [7] for the identification of the natural  $24,25(OH)_2D_3$ .

### 2. Experimental

### 2.1. Instruments

HPLC was performed with a Waters Associates chromatograph equipped with a 6000A pump, a U6K injector, a 254 nm ultraviolet detector and a 30 cm  $\times$  4 mm i.d. column of Microporasil. The mobil phase was *n*-hexane containing 2% (v/v) dichloromethane at a flow rate of 1 ml/min and a pressure of 42 kg/cm<sup>2</sup>.

The radioactivity was determined using a counting solution (Liquid Scintillator Unisolve 1, Koch-Light Lab.) and a liquid scintillation counter (Intertechnique Model SL 40).

## 2.2. Preparation and purification of biological radioactive 25,26(OH)<sub>2</sub>D<sub>3</sub>

Vitamin D-deficient chicks were given an injection of 6.5 nmol vitamin  $D_3$  in 0.05 ml ethanol subcutaneously 48 h before they were killed by decapitation. Kidneys were removed, placed in ice-cold sucrose (0.25 M) and homogenized to yield a 20% homogenate (w/v) in 0.19 M sucrose containing 15 mM Trisacetate (pH 7.4) and 1.9 mM magnesium acetate. An aliquot of the homogenate containing 200 mg kidney tissue was incubated in a 25 ml Erlenmeyer flask in a final 1.5 ml. The reaction mixture ultimately contained 0.19 M sucrose, 15 mM Tris-acetate (pH 7.4), 1.9 mM magnesium acetate and 25 mM succinate. The contents of the flask were flushed for 30 s with 100% oxygen and stoppered. The substrate  $(2.6 \text{ nmol } 25\text{-OH} \cdot [23,24\text{-}^{3}\text{H}]D_{3} \text{ dissolved in } 0.02 \text{ ml}$ 95% ethanol) was added to each vessel. The reaction mixtures were incubated at 37°C for 10 min. The reaction was stopped by the addition of 10 ml dichloromethane. Extraction was carried out by the dichloromethane extraction procedure in [8]. The dichloromethane extracts were applied directly to a Sephadex LH-20 column  $(2 \times 34 \text{ cm})$  eluted with

Elsevier/North-Holland Biomedical Press

Abbreviations: 25-OH-D<sub>3</sub>, 25-hydroxycholecalciferol; 1,25(OH)<sub>2</sub>D<sub>3</sub>, 1,25-dihydroxycholecalciferol; 25,26(OH)<sub>2</sub>D<sub>3</sub>, 25,26-dihydroxycholecalciferol; 24,25(OH)<sub>2</sub>D<sub>3</sub>, 24,25dihydroxycholecalciferol; TMS, trimethylsilyl; HPL(co-)C, high pressure liquid (co-)chromatography; TLC, thin layer chromatography

hexane:chloroform:methanol (9:1:1) to resolve 25,26(OH)<sub>2</sub>D<sub>3</sub> from 1,25(OH)<sub>2</sub>D<sub>3</sub> as in [9]. The 25,26(OH)<sub>2</sub>D<sub>3</sub> was applied in total to a HPLC system equipped with a DuPont Zorbax-SIL column (4.6 mm  $\times$  25 cm) developed with a solvent system of 9% isopropanol in hexane at 7000 p.s.i. The purified 25,26(OH)<sub>2</sub>D<sub>3</sub> was then used for co-chromatography with the synthetic material as described in sections 2.3 and 2.4.

### 2.3. Preparation of 3,25,26-Tris-TMS derivatives of 25,26(OH)<sub>2</sub>D<sub>3</sub>

Mixture of synthetic [3] 25R,26- and  $25S,26(OH)_2D_3$  (1.5  $\mu$ g each) were treated with trimethylsilylimidazol (4  $\mu$ l) in *n*-hexane (100  $\mu$ l) at 50°C for 30 min and left at room temperature for 12 h. The structure of 3,25,26-Tris-TMS derivatives was confirmed by TLC [2]. The solvent was evaporated under nitrogen, the residue dissolved in *n*-hexane containing 2% (v/v) dichloromethane, filtered and injected into the HPLC system.

### 2.4. Co-chromatography with radioactive 25,26(OH)<sub>2</sub>D<sub>3</sub>

In experiments with biologically generated  $25,26(OH)_2$ - $[23,24.^3H]D_3$ , the radioactive material was added to the mixture of epimeric 25R,26- and

 $25S,26(OH)_2D_3$  and treated as above. Fractions were collected at 30 s intervals and the radioactivity determined in each fraction.

### 3. Results

Figure 1 illustrates the separation of the Tris-TMS derivatives of 25R, 26- and  $25S, 26(OH)_2D_3$  achieved by HPCL on high surface area silica. The retention time for the 25S epimer was 62 min while that for the 25R one was 65 min.

In experiments with biologically generated  $25,26(OH)_2$ -[23,24- $^{3}H]D_3$  the radioactivity migrates with the derivative of  $25R,26(OH)_2D_3$ . Recovery for the radioactivity was 70%.

### 4. Discussion

Our results demonstrate clearly that the natural  $25,26(OH)_2D_3$  has a 25*R* configuration. This has been established first by preparing [3] synthetically the two C-25 epimers of  $25,26(OH)_2D_3$  and assigning [4] their respective configurations by X-ray studies. Then a method for separating the epimers as Tris-TMS ethers by HPLC was elaborated and it was found that



Fig.1. Separation of the Tris-TMS ethers of 25R,26- and  $25S,26(OH)_2D_3$  and co-chromatography of the Tris-TMS ether of radioactive biologically generated  $25,26(OH)_2D_3$  with the  $25R,26(OH)_2D_3$  derivative. The clear bars represent radioactivity in each fraction.

the derivative of  $25,26(OH)_2D_3$  of biological origin migrated with the  $25R,26(OH)_2D_3$  derivative.

It is of interest to note that another polar metabolite of vitamin  $D_3$ , 24,25(OH)<sub>2</sub> $D_3$  has been recently [7] identified with 24R,25(OH)<sub>2</sub> $D_3$ . But while the natural 24R,25(OH)<sub>2</sub> $D_3$  was superior to the synthetic 24S epimer in elevating serum phosphorus and in the calcification of bone in rachitic rats [7], the natural 25R,26(OH)<sub>2</sub> $D_3$  is surprisingly less effective [3] than 25S,26(OH)<sub>2</sub> $D_3$  in this biological system. The natural 25,26(OH)<sub>2</sub> $D_3$  isolated from porcine plasma has been found [5] inactive in the cure of rickets in rats.

### References

- Redel, J., Bell, P. A., Delbarre, F. and Kodicek, E. (1973) Ct. Rd. Hebd. Seanc. Acad. Sci. Paris 276 D, 2907-2910.
- [2] Redel, J., Bell, P. A., Bazely, N., Calando, Y., Delbarre, F. and Kodicek, E. (1974) Steroids 24, 463-475.
- [3] Redel, Y., Miravet, L., Bazely, N., Calando, Y., Carre, M. and Delbarre, F. (1977) Ct. Rd. Hebd. Seanc. Acad. Sci. Paris 285 D, 443-446.
- [4] Cesario, M., Guilhem, J., Pascard, C. and Redel, J. (1978) Tetrahedron Lett. 12, 1097–1098.
- [5] Suda, T., Deluca, H. F., Schnoes, H. K., Tanaka, Y. and Holick, M. F. (1970) Biochemistry 9, 4776-4780.
- [6] Tanaka, Y., Shepard, R. M., Deluca, H. F. and Schnoes, H. K. (1978) Biochem. Biophys. Res. Commun in press.
- [7] Tanaka, Y., Deluca, H. F., Ikekawa, N., Morisaki, M. and Koisumi, N. (1975) Arch. Biochem. Biophys. 170, 620-626.
- [8] Eisman, J. A., Hamstra, A. J., Kream, B. E. and Deluca, H. F. (1976) Arch. Biochem. Biophys. 176, 235-243.
- [9] Ribovich, M. L. and Deluca, H. F. (1978) Arch. Biochem. Biophys. 188, in press.